Esperion Therapeutics (ESPR) EBIAT: 2018-2025
Historic EBIAT for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$31.3 million.
- Esperion Therapeutics' EBIAT fell 6.13% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.8 million, marking a year-over-year decrease of 21.97%. This contributed to the annual value of -$51.7 million for FY2024, which is 75.27% up from last year.
- Latest data reveals that Esperion Therapeutics reported EBIAT of -$31.3 million as of Q3 2025, which was down 146.23% from -$12.7 million recorded in Q2 2025.
- Esperion Therapeutics' 5-year EBIAT high stood at $61.0 million for Q1 2024, and its period low was -$90.9 million during Q1 2021.
- Its 3-year average for EBIAT is -$31.4 million, with a median of -$40.5 million in 2025.
- Per our database at Business Quant, Esperion Therapeutics' EBIAT soared by 198.87% in 2024 and then tumbled by 166.30% in 2025.
- Over the past 5 years, Esperion Therapeutics' EBIAT (Quarterly) stood at -$65.1 million in 2021, then increased by 14.79% to -$55.5 million in 2022, then dropped by 1.54% to -$56.3 million in 2023, then skyrocketed by 62.16% to -$21.3 million in 2024, then decreased by 6.13% to -$31.3 million in 2025.
- Its EBIAT stands at -$31.3 million for Q3 2025, versus -$12.7 million for Q2 2025 and -$40.5 million for Q1 2025.